Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
SARS-CoV-2 main protease drug design, assay development, and drug resistance studies
Conspectus SARS-CoV-2 is the etiological pathogen of the COVID-19 pandemic, which led
to more than 6.5 million deaths since the beginning of the outbreak in December 2019. The …
to more than 6.5 million deaths since the beginning of the outbreak in December 2019. The …
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
Vaccines and drugs have helped reduce disease severity and blunt the spread of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, ongoing virus …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, ongoing virus …
Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir
X Jiang, H Su, W Shang, F Zhou, Y Zhang… - Nature …, 2023 - nature.com
The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great …
respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great …
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …
Evolutionary and structural insights about potential SARS-CoV-2 evasion of nirmatrelvir
The US FDA approval of PAXLOVID, a combination therapy of nirmatrelvir and ritonavir has
significantly boosted our morale in fighting the COVID-19 pandemic. Nirmatrelvir is an …
significantly boosted our morale in fighting the COVID-19 pandemic. Nirmatrelvir is an …
Small molecules in the treatment of COVID-19
S Lei, X Chen, J Wu, X Duan, K Men - Signal transduction and targeted …, 2022 - nature.com
The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …
societies and economies. Until now, effective therapeutics against COVID-19 are in high …
Alkyne derivatives of SARS-CoV-2 main protease inhibitors including nirmatrelvir inhibit by reacting covalently with the Nucleophilic Cysteine
Nirmatrelvir (PF-07321332) is a nitrile-bearing small-molecule inhibitor that, in combination
with ritonavir, is used to treat infections by severe acute respiratory syndrome coronavirus-2 …
with ritonavir, is used to treat infections by severe acute respiratory syndrome coronavirus-2 …
Recent advances in SARS-CoV-2 main protease inhibitors: from nirmatrelvir to future perspectives
A Citarella, A Dimasi, D Moi, D Passarella, A Scala… - Biomolecules, 2023 - mdpi.com
The main protease (Mpro) plays a pivotal role in the replication of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target …
syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target …
Fluorine-a small magic bullet atom in the drug development: perspective to FDA approved and COVID-19 recommended drugs
During the last twenty years, organic fluorination chemistry established itself as an important
tool to get a biologically active compound. This belief can be supported by the fact that every …
tool to get a biologically active compound. This belief can be supported by the fact that every …